Research across Cancer
Related studies from across the Cancer family.
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma
EGFR Inhibitors Show Activity in Advanced Anal Squamous Cell Carcinoma
This meta-analysis of 404 patients evaluated EGFR inhibitors (cetuximab and panitumumab) for anal squamous cell carcinoma. The analysis foun…
New analysis shows that EGFR inhibitors like cetuximab and panitumumab may improve response rates for patients with advanced anal squamous c…
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation
Low blood counts and high inflammation may signal worse survival for anal cancer patients
This systematic review and meta-analysis of 3589 patients with anal squamous cell carcinoma found that elevated neutrophil-to-lymphocyte rat…
For patients with anal cancer, low hemoglobin and high inflammation markers linked to poorer survival in this analysis of nearly 3,600 peopl…
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
Can New Treatments Help Fight HIV-Related Anal Cancer More Effectively?
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-r…
A new trial tests gentler radiation and chemotherapy for low-risk HIV anal cancer, while adding immunotherapy for high-risk cases to improve…